Novartis AG (NVS)

87.07
0.72 0.83
NYSE : Health Technology
Prev Close 86.35
Open 87.64
Day Low/High 86.77 / 87.80
52 Wk Low/High 74.97 / 96.31
Volume 1.91M
Avg Volume 1.89M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 217.80B
EPS 5.50
P/E Ratio 16.08
Div & Yield 1.84 (2.13%)

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APLP, DCI, DWRE, ISIL, MBT, NVS, STC Downgrades: AMG, COH, EQS, GIG, LECO, MITK, NEWM, TRNC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Trade-Ideas: Novartis (NVS) Is Today's Pre-Market Leader Stock

Trade-Ideas: Novartis (NVS) Is Today's Pre-Market Leader Stock

Trade-Ideas LLC identified Novartis (NVS) as a pre-market leader candidate

'Brexit': Stocks to Avoid on June 24

'Brexit': Stocks to Avoid on June 24

Stay away from banks, but pharmaceuticals and tech stocks look good, analysts say.

Meet the Marijuana Industry Money-Man, Rob Hunt of Tuatara Capital

Meet the Marijuana Industry Money-Man, Rob Hunt of Tuatara Capital

It was all about the green at this week's Cannabis World Congress in New York.

Jim Cramer's 'Mad Money' Recap: The Bull Is Napping

Jim Cramer's 'Mad Money' Recap: The Bull Is Napping

The rally has been strong and the bull market is taking a deserved rest, Cramer says.

3 Stocks Pulling The Health Care Sector Downward

3 Stocks Pulling The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

What You Need to Know About Biotech IPOs This Year

What You Need to Know About Biotech IPOs This Year

Here's the lowdown on the biotech companies that have come public this year.

Pharma Giant Novartis Is a Great Bargain for Investors

Pharma Giant Novartis Is a Great Bargain for Investors

Novartis has had to cope with the expiration of some patents, but it should benefit from its varied products and significant investment in research and development.

Endo Could Be the Next Activist Target in Generics

Problems with mesh products and high leverage might scare away a potential buyer. 

Analysts Differ On Impact Of Valeant's Rejected Takeover Bid

Analysts Differ On Impact Of Valeant's Rejected Takeover Bid

Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.

Finding the path forward

Finding the path forward

Huge uncertainty hangs over the markets in 2016

Heavy Trading On Novartis (NVS) Before Market Open

Heavy Trading On Novartis (NVS) Before Market Open

Trade-Ideas LLC identified Novartis (NVS) as a pre-market mover with heavy volume candidate

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

Ziopharm Subpar Cancer Therapies Can't Support Lofty Market Valuation

Ziopharm is its own mini biotech bubble, held aloft unjustifiably because of its interlocking relationship with Intrexon, the synthetic biology company majority-owned by R.J. Kirk.

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Global Pharma Players Likely to Flock to Medivation

Global Pharma Players Likely to Flock to Medivation

AstraZeneca, Bayer, Eli Lilly and Merck are just a few of the names that may join a bidding war for the cancer drug maker, analysts say.

Jim Cramer -- Valeant Has Too Many 'What Ifs' Right Now

Jim Cramer -- Valeant Has Too Many 'What Ifs' Right Now

New Chairman and CEO Joe Papa can't stop the world from gunning for Valeant.

Cramer Talks Debt, Pipeline With Valeant CEO

Cramer Talks Debt, Pipeline With Valeant CEO

TheStreet's founder shares his thoughts after his one-on-one interview with Valeant's new chairman and CEO.

2 Dirt-Cheap Big Pharma Stocks Poised to Beat Biotech's Bad Rap

2 Dirt-Cheap Big Pharma Stocks Poised to Beat Biotech's Bad Rap

The drug industry is getting pilloried in the court of public opinion, but that only creates buying opportunities for you.

Sanofi First Quarter Shows Why It Wants but Doesn't Need Medivation

Sanofi First Quarter Shows Why It Wants but Doesn't Need Medivation

The San Francisco target rejects the $9.3 billion offer, but biotech growth and a healthy pipeline mean Sanofi isn't desperate for Medivation's cancer treatments.

April 25 Premarket Briefing: 10 Things You Should Know

April 25 Premarket Briefing: 10 Things You Should Know

U.S. stock futures slide Monday while European and Asian shares slump ahead of rate-setting meetings this week of the Federal Reserve and the Bank of Japan.

Doha Oil Talks Fail: What It Means for the Markets in the Week Ahead

Doha Oil Talks Fail: What It Means for the Markets in the Week Ahead

The failure of OPEC's latest attempts to hammer out an oil production freeze is likely to have dire consequences for global equity markets.

European Stocks Stabilize as Health Care Gains

European Stocks Stabilize as Health Care Gains

European stocks stabilize on Wednesday, with health care stocks among the gainers as Pfizer reportedly prepares to announce the termination of its $160 billion deal for Allergan.

Fed Worries, Crude Oil Team Up to Beat Down Wall Street

Fed Worries, Crude Oil Team Up to Beat Down Wall Street

Renewed worries over the Federal Reserve's rate hike plans and another selloff in crude oil prices team up to beat down Wall Street in a sour start to the week.

Stocks Extend Drop on Interest Rates Focus

Stocks Extend Drop on Interest Rates Focus

Stocks extend their decline by mid-afternoon Monday on renewed worries the Federal Reserve could raise rates sooner than Wall Street anticipates.

Pfizer Tops List of Best Biopharmaceutical Brands

Pfizer Tops List of Best Biopharmaceutical Brands

Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top 10 biopharmaceutical brands.

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer Tops Interbrand's List of Best Biopharmaceutical Brands

Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.

3 Stocks Pushing The Drugs Industry Downward

3 Stocks Pushing The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Trade-Ideas: Novartis (NVS) Is Today's Pre-Market Laggard Stock

Trade-Ideas: Novartis (NVS) Is Today's Pre-Market Laggard Stock

Trade-Ideas LLC identified Novartis (NVS) as a pre-market laggard candidate

10 Women Who Would Be a Great Addition to Any Company's Board

10 Women Who Would Be a Great Addition to Any Company's Board

Seven companies in the S&P 500 have no women on their boards. Maybe they're having trouble finding the right women? We aren't. Here are 10 that would make great additions.

Novartis (NVS) Stock Downgraded at Leerink

Novartis (NVS) Stock Downgraded at Leerink

Novartis (NVS) was downgraded to ‘market perform’ from ‘outperform’ at Leerink.

TheStreet Quant Rating: A- (Buy)